MediGene to Present at the 3rd Annual Rodman & Renshaw Global Healthcare Conference in Monte Carlo
Webcast will be available at www.medigene.com
Martinsried/Munich - San Diego, May 9, 2006. The German-American biotech company MediGene AG (Frankfurt, TecDAX, Prime Standard: MDG) announced today that the company will be presenting at the 3rd Annual Rodman & Renshaw Global Healthcare Conference in Monte Carlo, on Tuesday May 16, 2006, at 12:40 p.m. local time, at the The Le Meridien Sea Club. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on current clinical, business and finance developments. The webcast of the presentation will be available on the internet at www.medigene.com.
MediGene possesses a mature drug pipeline with a drug* available on the European market, another drug undergoing approval procedure in the US (Polyphenon® E Ointment** for the treatment of genital warts) and several oncological drug candidates in clinical development. In addition, MediGene owns cutting-edge platform technologies with the EndoTAG as well as the oncolytic HSV technologies. The drug candidate EndoTAG-1** (clinical phase II in pancreatic cancer) aims at “starving out” tumors by destroying the supplying blood vessels. It builds on the successful new therapeutic principle of anti-angiogenesis (inhibition of vascularization), and yet provides an innovative variation thanks to its novel mode of action (vascular disruptive agent). MediGene’s innovative oncolytic HSV (herpes simplex viruses) (phase I/II in glioma and liver metastases) are modified for the selective destruction of tumor cells without harming healthy tissue.
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM and EndoTAGTM are trademarks of MediGene AG, Polyphenon® E is a trademark of Mitsui Norin.
* For legal reasons, product name and indication are not mentioned on the internet (German Law on Drug Advertising)
** temporary name while under development
- Contact Information
- Julia Hofmann
- Public Relations
- MediGene AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.